Brief: Abionyx H1 Operating Loss Deepens To EUR 2.6 Mln

Abionyx Pharma SA

09/09/2021 17:53

Sept 9 (Reuters) - ABIONYX PHARMA SA  ABNX.PA :
    * H1 FINANCIAL UPDATE
    * H1 OPERATING LOSS EUR 2.6 MILLION VERSUS LOSS OF EUR 1.04
MILLION YEAR AGO
    * H1 NET LOSS EUR 2.55 MILLION VERSUS LOSS OF EUR 1.0
MILLION YEAR
AGO
    * PROGRESS IN THE FULLY-FUNDED PHASE 2A CLINICAL TRIAL,
RACERS,
EVALUATING CER-001 IN SEPSIS AT HIGH RISK OF DEVELOPING ACUTE
KIDNEY INJURY
    * END-JUNE CASH AND CASH EQUIVALENTS EUR 4.83 MILLION VERSUS
EUR
8.81 MILLION YEAR AGO
    * ORPHAN DRUG DESIGNATION STATUS GRANTED FOR CER-001 FOR
LECITHIN
CHOLESTEROL ACYLTRANSFERASE (LCAT) DEFICIENCY AS BOTH A RENAL
DISEASE AND AN OPHTHALMIC DISEASE
    * REVENUE OF EUR 27,000 IN Q1 VERSUS NO REVENUE YEAR AGO

Source text for Eikon:  ID:nNDL8VJpYb 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))